A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3970 for 12 Weeks in Adult Subjects With Active Primary Sjögren's Syndrome
Latest Information Update: 20 Sep 2023
Price :
$35 *
At a glance
- Drugs GLPG 3970 (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLIDER
- Sponsors Galapagos NV
- 05 Feb 2022 This trial has been completed in Hungary (Date of the global end of the trial : 27-Jan-2022), according to European Clinical Trials Database record.
- 26 Jan 2022 Status changed from active, no longer recruiting to discontinued.
- 13 Jan 2022 This trial has been completed in Greece (end date:2021-12-27), according to European Clinical Trials Database record.